Publications by authors named "Marc Geirnaert"

Claim this Profile
R
Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.
Harshal Senthil, Scott Streilein, Theresa Whiteside, Leonard Minuk, Ivan Landego, Marc Geirnaert

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma.
Rami Kotb, Marc Geirnaert, Emily Rimmer, Vi Dao, Jayne Kasian

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Kelvin Kar-Wing Chan, Pam Takhar, William K Evans, Rebecca E Mercer, Avram Denburg, Marc Geirnaert

BMJ Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba.
Kaitlin Quinlan, Marc Geirnaert, Rami Kotb, Vi Dao, Leonard Minuk

J Oncol Pharm Pract· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Pam Takhar, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E Mercer

Curr Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study.
Arjun A Raghavan, Sid Goutam, Grace Musto, Marc Geirnaert, Carrie Ye

J Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.
Andrew Walker, Alexandre Chan, Constanza Cortés Labra, Mario L de Lemos, Marc Geirnaert

J Oncol Pharm Pract· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
Jiayu Yang, Lin Yang, Bryan Tordon, Oliver Bucher, Zoann Nugent, Marc Geirnaert

Curr Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Vanessa Quang Nguyen, Marc Geirnaert

J Oncol Pharm Pract· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Ambica Parmar, Wei Fang Dai, Francois Dionne, Marc Geirnaert, Avram Denburg

Curr Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canada's First Joint Oncology-Allergy Clinic: Successful Desensitization to Trastuzumab Following Severe Anaphylactic Reaction in Which Epinephrine Was Inappropriately Withheld.
Madeline Robinson, Marc Geirnaert, Brady Anderson, Lundy McKibbin

Curr Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Nicole Bourrier, Ivan Landego, Oliver Bucher, Mandy Squires, Erin Streu, Marc Geirnaert

BMC Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Wei Fang Dai, Erica Craig, Brent Fraser, Alex Chambers, Helen Mai, Marc Geirnaert

Curr Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Marc Geirnaert, Jacy Howarth, Kristen Martin, Chad Ricard, Scott Streilein

J Oncol Pharm Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Christine Leong, Piotr Czaykowski, Marc Geirnaert, Alan Katz, Roxana Dragan

Can J Public Health· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Off-label infusion of biosimilar bevacizumab: A provincial experience.
Marc Geirnaert, Jacy Howarth, Curtis Kellett, Kristen Martin, Scott Streilein

J Oncol Pharm Pract· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Julian Nam, Robert Milenkovski, Simon Yunger, Marc Geirnaert, Kristjan Paulson

J Med Econ· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis